SC
TVRD

Steven Cohen’s Tvardi Therapeutics TVRD Stock Holding History

Steven Cohen’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-694
Closed -$385K – 1092
2017
Q2 		$385K Sell
694
-695
-50% -$441K ﹤0.01% 778
2017
Q1 		$920K Buy
+1,389
New +$742K 0.01% 745

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Steven Cohen's TVRD Position: Q4 2023 in Review

Steven Cohen sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 3 shares — an estimated $195 sold.

Steven Cohen first reported a position in TVRD in Q2 2015 and held it in 12 quarters. The position peaked at $8.94M in Q4 2015. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Steven Cohen reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Steven Cohen sold 3 Tvardi Therapeutics shares in Q4 2023, an estimated $195.
  • Steven Cohen first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 12 quarters.
  • Steven Cohen's Tvardi Therapeutics position peaked at $8.94M in Q4 2015.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.